Risk factor
Strong & resilient to price shocks
Profitability factor
Solid dividends
About
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasonably priced
Target Price
The average target price of HYPE3.SA is 30.5 and suggests 28.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to